Mirai Medical

Mirai Medical, founded in 2019 and based in Galway, Ireland, is developing the ePORE® therapy, a platform utilizing pulsed electric fields (PEF) for the endoscopic ablation of tissue, targeting gastrointestinal and skin cancers. The technology aims to offer a precise, non-thermal treatment that could reduce procedure times and complications compared to existing standards. As a private, likely pre-revenue entity, the company is in the clinical development and regulatory approval stage, positioning itself in the growing interventional endoscopy market. Its success hinges on clinical validation, regulatory clearance, and commercial execution in a competitive landscape.

Endoscopic pulsed electric field (PEF) ablation platform (ePORE®) for non-thermal, precise tissue destruction.

Mirai Medical competes in the tissue ablation market against large, established players like Boston Scientific (RFA), Medtronic, and J&J, as well as other companies with cryoablation and microwave technologies. Its differentiation hinges on the purported benefits of non-thermal pulsed electric field ablation, such as precision and tissue selectivity.